Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M95.8Revenue $M0.3Net Margin (%)0Z-Score-13.3
Enterprise Value $M82.2EPS $-0.2Operating Margin %0F-Score2
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yY
Price/Book7.910-y EBITDA Growth Rate %0.2Quick Ratio5.3Cash flow > EarningsN
Price/Sales05-y EBITDA Growth Rate %-2.0Current Ratio5.3Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-84.6Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-104.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M89.6ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with ONCY

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ONCYJean-Marie Eveillard 2014-09-30 Sold Out $0.563 - $1.66
($1.28)
$ 1.07-16%Sold Out0
ONCYJean-Marie Eveillard 2014-06-30 Reduce$1.23 - $1.99
($1.43)
$ 1.07-25%Reduce -55.85%188,600
ONCYJean-Marie Eveillard 2013-03-31 Buy $2.99 - $4.67
($3.6)
$ 1.07-70%New holding, 450000 sh.450,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ONCY is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


ONCY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Dillahunty, Mary AnnSenior Officer 2014-11-13Sell1,201$0.6119.67view
Hohol, Linda Margaret OwerriDirector 2014-10-20Buy10,000$0.5630.36view
Dinning, James FrancisDirector 2014-10-03Buy10,000$0.6119.67view
Thompson, BradleyDirector, Senior Officer 2014-10-03Buy10,000$0.6119.67view
Levy, EdwinDirector 2014-10-03Buy16,000$0.6217.74view
Dinning, James FrancisDirector 2014-10-02Buy20,000$0.621.67view
Hohol, Linda Margaret OwerriDirector 2014-08-12Buy6,800$1.51-51.66view
Dinning, James FrancisDirector 2014-07-04Buy15,000$1.45-49.66view
Levy, EdwinDirector 2014-01-03Buy5,900$1.72-57.56view
Dinning, James FrancisDirector 2013-12-13Buy5,000$1.62-54.94view

Press Releases about ONCY :

    Quarterly/Annual Reports about ONCY:

      News about ONCY:

      Articles On GuruFocus.com
      No related article found.

      More From Other Websites
      Nasdaq stocks posting largest volume increases Feb 27 2015
      Oncolytics Biotech Completes Enrolment for Reolysin Study - Analyst Blog Feb 19 2015
      Oncolytics' Reolysin Gets Another Orphan Drug Status - Analyst Blog Feb 18 2015
      Canada Stocks to Watch: Cenovus, Western Forest and Oncolytics Feb 18 2015
      Oncolytics Biotech® Inc. Announces Completion of Enrollment in Randomized Phase II Colorectal... Feb 18 2015
      Oncolytics Biotech® Inc. Announces Completion of Enrollment in Randomized Phase II Colorectal... Feb 18 2015
      Oncolytics Biotech® Inc. Announces Completion of Enrollment in Randomized Phase II Colorectal... Feb 18 2015
      Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for... Feb 17 2015
      Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for... Feb 17 2015
      Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for... Feb 17 2015
      Oncolytics' Reolysin Gets Orphan Status for Ovarian Cancer - Analyst Blog Feb 12 2015
      Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Ovarian... Feb 11 2015
      Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Ovarian... Feb 11 2015
      Oncolytics Seeks Orphan Drug Status for Reolysin in the U.S. - Analyst Blog Feb 10 2015
      Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for High... Feb 09 2015
      Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for High... Feb 09 2015
      Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for High... Feb 09 2015
      Oncolytics Biotech® Inc. Announces Filing for Orphan Designation with the EMA for Pancreatic and... Dec 22 2014
      Oncolytics Biotech® Inc. Announces Filing for Orphan Designation with the EMA for Pancreatic and... Dec 22 2014
      Oncolytics Biotech® Inc. Announces Filing for Orphan Designation with the EMA for Pancreatic and... Dec 22 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK